#USA #Boston #Ginkgo Bioworks #Nebula #Araceli Biosciences

Revolutionizing Drug Research with High-Content Imaging

In a remarkable stride towards transforming drug research, Araceli Biosciences and Ginkgo Bioworks have announced the integration of Araceli's Endeavor® High-Content Imaging system into Ginkgo's autonomous lab, Nebula. This collaboration marks a significant advancement in cellular imaging technology, combining speed, efficiency, and real-time analysis to accelerate the pace of scientific discovery.

Enhancing Research Capabilities

The Endeavor system is hailed as the fastest high-content imaging device worldwide, allowing researchers at Ginkgo to conduct cellular imaging with real-time analysis. This integration is not merely a technical upgrade; it is a transformative leap that equips scientists with curated datasets essential for training and validating AI models in drug discovery. The autonomy of the Nebula lab empowers dozens of researchers daily, who utilize over 100 modular Reconfigurable Automation Carts (RACs) to streamline their workloads and enhance productivity.

The RACs, which include robotic arms and automated sample transport, enable teams to conduct experiments and receive data with unprecedented speed. In fact, the system is capable of analyzing a 1536-well plate in less than four minutes, continuously performing alongside active experiments without the need for significant downtime. Such efficiency vastly reduces the footprint required for traditional laboratory setups, eliminating the need for large, space-consuming laboratory furniture.

Real-Time Problem Solving

One of the standout features of the Endeavor system is its integration with Araceli’s ClaireRT™ software, which allows for real-time image analysis during data capture. Should an analysis reveal that certain wells do not meet predefined criteria, the system can notify laboratory personnel to intervene or pause the imaging process, ensuring that any operational issues are addressed promptly before continuing. This capability is crucial for maintaining the integrity of research findings and optimizing experimental outcomes.

Matt Beaudet, President and CEO of Araceli Biosciences, emphasized the transformative nature of this partnership, stating, "The next generation of AI in drug discovery requires biological data on a completely different scale. The lab is evolving; it now generates cellular data, interprets what it sees, and reacts in real-time." This dynamic approach profoundly shifts how biological research is conducted, making the process more efficient and integrated.

Enhanced Autonomy

According to Jason Kelly, Co-founder and CEO of Ginkgo Bioworks, adding state-of-the-art equipment like the Endeavor system increases the value of an autonomous lab exponentially. By providing scientists with leading-edge imaging capabilities connected seamlessly to other lab devices, researchers can capitalize on the best tools available in the field. Essentially, this innovation underscores the potential of autonomous laboratories to streamline workflows and uplift research productivity.

About Araceli Biosciences

Araceli Biosciences is renowned for its rapid development of high-content imaging technologies and AI-powered analytic software designed for automated laboratories. Their integrated solutions deliver cellular insights in real-time, empowering researchers to make informed decisions at every phase of their experiments. This functionality is vital in helping biotech and pharmaceutical companies scale their research outcomes more effectively and with greater reliability.

For more information about Araceli Biosciences and their cutting-edge technologies, you can visit aracelibio.com.

About Ginkgo Bioworks

Ginkgo Bioworks is dedicated to simplifying the technical design of biological processes. The company provides autonomous laboratories that replace manual labor with robotics, drastically improving scientists' productivity levels. Their proprietary lab, Nebula, is also available as a 'cloud lab' through their contract research services.

By focusing on the automation and scalability of biological data generation, Ginkgo Bioworks seeks to make experimental science more accessible. Visit ginkgo.bio to learn more about how they are reshaping the landscape of biotech and life sciences.

Conclusion

The collaboration between Araceli Biosciences and Ginkgo Bioworks serves as a pivotal point in the evolution of drug discovery methodologies, heralding a future where speed, efficiency, and real-time analysis are paramount in the pursuit of scientific knowledge. As they continue to push the boundaries of what is possible in cellular imaging and automation, the implications of their work will likely have profound effects on the broader field of biomedicine and beyond.